Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)
The Epidemiology of Atopic Dermatitis, Associated Comorbidities, and Treatment Patterns in the United Kingdom (UK)
1 other identifier
observational
148,166
1 country
1
Brief Summary
Atopic dermatitis (AD), commonly called eczema, is one of the most frequently occurring skin conditions. It is estimated to affect around one fifth of children in developed countries and is also becoming increasingly common in less developed countries. Exact estimates of how common eczema is, vary considerably and there has not been an in-depth analysis of the number of people with eczema in the UK. It is also unclear which groups of people are most affected and which treatment options are being used. Most people with eczema are managed by their general practitioner (GP) with only a few people requiring specialist care. GP records therefore provide an excellent opportunity to explore how common eczema is and which treatments are being used currently.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2019
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 17, 2019
CompletedFirst Posted
Study publicly available on registry
January 30, 2019
CompletedStudy Start
First participant enrolled
February 1, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 4, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
November 4, 2020
CompletedResults Posted
Study results publicly available
June 6, 2025
CompletedJune 6, 2025
January 1, 2025
1.8 years
January 17, 2019
January 30, 2023
May 19, 2025
Conditions
Outcome Measures
Primary Outcomes (12)
Prescription Rates for Atopic Dermatitis Related Treatments: Emollients and Soap Substitutes
Proportion of the arm/group receiving at least one prescription for emollients and soap substitutes.
Jan - Dec 2018 inclusive
Prescription Rates for Atopic Dermatitis Related Treatments: Mild Topical Corticosteroids (TCS)
Proportion of the arm/group receiving at least one prescription for mild topical corticosteroids (atopic dermatitis related treatment)
Jan - Dec 2018 inclusive
Prescription Rates for Atopic Dermatitis Related Treatments: Moderate Topical Corticosteroids (TCS)
Proportion of the arm/group receiving at least one prescription for moderate topical corticosteroids (an atopic dermatitis related treatment)
Jan - Dec 2018 inclusive
Prescription Rates for Atopic Dermatitis Related Treatments: Potent Topical Corticosteroids (TCS)
Proportion of the arm/group receiving at least one prescription for potent topical corticosteroids (an atopic dermatitis related treatment)
Jan - Dec 2018 inclusive
Prescription Rates for Atopic Dermatitis Related Treatments: Very Potent Topical Corticosteroids (TCS)
Proportion of the arm/group receiving at least one prescription for very potent topical corticosteroid (an atopic dermatitis related treatment)
Jan - Dec 2018 inclusive
Prescription Rates for Atopic Dermatitis Related Treatments: Topical Calcineurin Inhibitors (TCI)
Proportion of the arm/group receiving at least one prescription for a topical Calcineurin Inhibitor (an atopic dermatitis related treatment)
Jan - Dec 2018 inclusive
Prescription Rates for Atopic Dermatitis Related Treatments: Topical Antimicrobials
Proportion of the arm/group receiving at least one prescription for topical antimicrobials.
Jan - Dec 2018 inclusive
Prescription Rates for Atopic Dermatitis Related Treatments: Antihistamin
Proportion of the arm/group receiving at least one prescription for antihistamin.
Jan - Dec 2018 inclusive
Prescription Rates for Atopic Dermatitis Related Treatments: Systemic Immuno-modulatory Therapy
Proportion of the arm/group receiving at least one prescription for Systemic immuno-modulatory therapy
Jan - Dec 2018 inclusive
Prescription Rates for Atopic Dermatitis Related Treatments: Oral Corticosteroids
Proportion of the arm/group receiving at least one prescription for oral corticosteroids
Jan - Dec 2018 inclusive
Specialist Referrals
Specialist dermatology referral rate in 2018
Jan - Dec 2018 inclusive
Primary Care Referrals
Annual rate of primary care consultations in 2018
Jan - Dec 2018 inclusive
Study Arms (1)
Active atopic dermatitis
People fulfilling the diagnostic criteria for active atopic dermatitis during the calendar year 2018, and meeting the inclusion criteria and registered with one of the study practices for one or more years during the study period.
Interventions
Eligibility Criteria
Adults and children with atopic dermatitis identified from routinely collected healthcare records using a validated algorithm.
You may qualify if:
- All paediatric and adult patients registered with an Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) contributing GP practice during the study period (2008-2018) and with at least one year of follow-up.
You may not qualify if:
- The presence of psoriasis, photodermatitis, or ichthyosis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Momentum Datalead
- Pfizercollaborator
- Oxford Royal College of General Practitioners Research and Surveillance Centrecollaborator
Study Sites (1)
Momentum Data Ltd
London, WC1X 8QT, United Kingdom
Related Publications (3)
de Lusignan S, Alexander H, Broderick C, Dennis J, McGovern A, Feeney C, Flohr C. The epidemiology of eczema in children and adults in England: A population-based study using primary care data. Clin Exp Allergy. 2021 Mar;51(3):471-482. doi: 10.1111/cea.13784. Epub 2020 Nov 26.
PMID: 33179341DERIVEDde Lusignan S, Alexander H, Broderick C, Dennis J, McGovern A, Feeney C, Flohr C. Patterns and trends in eczema management in UK primary care (2009-2018): A population-based cohort study. Clin Exp Allergy. 2021 Mar;51(3):483-494. doi: 10.1111/cea.13783. Epub 2020 Nov 23.
PMID: 33176023DERIVEDde Lusignan S, Alexander H, Broderick C, Dennis J, McGovern A, Feeney C, Flohr C. Epidemiology and management of atopic dermatitis in England: an observational cohort study protocol. BMJ Open. 2020 Sep 16;10(9):e037518. doi: 10.1136/bmjopen-2020-037518.
PMID: 32938595DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Carsten Flohr
- Organization
- Guy's & St Thomas' NHS Foundation Trust
Study Officials
- STUDY DIRECTOR
Andrew McGovern, MD
Momentum Data Ltd
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 17, 2019
First Posted
January 30, 2019
Study Start
February 1, 2019
Primary Completion
November 4, 2020
Study Completion
November 4, 2020
Last Updated
June 6, 2025
Results First Posted
June 6, 2025
Record last verified: 2025-01
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL
- Time Frame
- There is no pre-specified time-frame for data availability; this will be considered on an individual basis for each request.
- Access Criteria
- As above
All individual patient data (IPD) can be made available to bone fide researchers subject to appropriate checks and approvals made by Momentum Data, the RCGP RSC, and the University of Surrey and subject to the completion of information governance training.